Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent price action, combined with deteriorating moving averages and mixed signals from momentum oscillators, suggests caution for investors amid a challenging market backdrop.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

AstraZeneca Pharma India Ltd. delivered a mixed performance in Q3 FY26 (Oct-Dec'25), with robust revenue growth overshadowed by significant margin compression and profit decline. The pharmaceutical major reported net profit of ₹32.59 crores, down 39.89% quarter-on-quarter from ₹54.22 crores in Q2 FY26, though up 5.64% year-on-year from ₹30.85 crores in Q3 FY25. The stock has declined 4.13% following the results announcement, trading at ₹8,696.15 and reflecting investor concerns about operational efficiency despite strong topline momentum.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a subtle shift in its technical momentum, moving from a bearish to a mildly bearish trend as of early 2026. Despite a modest day gain of 0.97%, the stock’s technical indicators present a complex picture, with some signals suggesting caution while others hint at potential stabilisation. This article analyses the recent technical parameter changes, key momentum indicators, and how Astrazeneca’s performance compares with broader market benchmarks.

Astrazeneca Pharma India Ltd is rated Sell by MarketsMOJO, with this rating last updated on 02 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Astrazeneca Pharma India Ltd has experienced a notable shift in price momentum, with technical indicators signalling a transition from mildly bearish to bearish trends. Despite a marginal day gain of 0.12%, the stock’s broader technical landscape suggests caution for investors amid weakening momentum and mixed signals from key oscillators and moving averages.

Astrazeneca Pharma India Ltd has seen its investment rating downgraded from Hold to Sell as of 2 January 2026, reflecting a shift in technical indicators and valuation metrics despite solid financial performance. The downgrade is primarily driven by a deteriorating technical trend, expensive valuation multiples, and mixed signals from financial and quality parameters, signalling caution for investors in the Pharmaceuticals & Biotechnology sector.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance as of early January 2026. This transition is underscored by a combination of technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling a cautious outlook for investors amid recent price declines and mixed market signals.

Astrazeneca Pharma India Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 07 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Astrazeneca Pharma India Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of late December 2025. Despite a year-to-date return of 21.3%, outperforming the Sensex by a wide margin, recent technical indicators suggest a more cautious outlook for investors as mixed signals emerge across key momentum and trend metrics.

Astrazeneca Phar has undergone a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. This adjustment comes amid a backdrop of strong profitability metrics and premium valuation levels within the Pharmaceuticals & Biotechnology sector.

Astrazeneca Phar has experienced a revision in its market evaluation, reflecting a nuanced shift in its financial and technical outlook. The pharmaceutical company’s recent assessment highlights a blend of strong operational fundamentals alongside valuation concerns, prompting a reassessment of its standing within the Pharmaceuticals & Biotechnology sector.